Emerging therapies for sepsis and septic shock

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 5, 1998, Pages 738-743

  Oh, H M L ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Endotoxin; Interleukin; Monoclonal antibody; Tumour necrosis factor

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTITHROMBIN III; APROTININ; BN 502021; CENTOXIN; CORTICOSTEROID; ELASTASE INHIBITOR; HIRUDIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NITRIC OXIDE; OKT 4; PHOSPHORYL LIPID A; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; HUMAN; IMMUNOREGULATION; SEPSIS; SEPTIC SHOCK; TREATMENT PLANNING;

EID: 0032413541     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parillo J E. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-7.
2. American College of Chest Physicians / Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-74.
3. Harris R L, Muscher D M, Bloom K, Gathe J, Rice L, Sugarman B, et al. Manifestations of sepsis. Arch Intern Med 1987; 147:1895-906.
4. Parker M M, Shelhamer J H, Natanson C, Ailing D W, Parrillo J E. Serial cardiovascular patterns in survivors and non-survivors of human septic shock. Heart rate as an early prediction of prognosis. Crit Care Med 1987; 15:923-9.
5. Heard S O, Perkins M W, Fink M P. Tumour necrosis factor - alpha causes myocardial depression in guinea pigs. Crit Care Med 1992; 20:523-7.
6. Kumar A, Kosuri R, Kandula P, Olson J, Dee L, Olson J, et al. Cardiomyocy te depression induced by human septic serum is mediated by nitric oxide and cyclic GMP generation. Crit Care Med 1994; 22:A119.
7. Pinsky M R. Cause-specific management of shock. Postgrad Med 1983; 73:127-35, 138-40, 145.
8. Braude A L. Bacterial endotoxins. In: Braude A L, editor. Infectious Diseases and Medical Microbiology. 2nd ed. Philadelphia: WB Saunders, 1986:51-60.
9. Wenzel R P, Pinsky M R, Ulevitch R J, Young L. Current understanding of sepsis. Clin Infect Dis 1996; 22:407-13.
10. Lynn W A, Cohen J. Management of septic shock. J Infect Dis 1995; 30:207-12.
11. Tobias P S, Ulevitch R J. Lipopolysaccharide-binding protein and CD14 in the lipopolysaccharide-dependent activation of cells. Chest 1994; 105(suppl 3):485-505.
12. Bone R C. Gram-positive bacteria and sepsis. Arch Intern Med 1994; 154:26-34.
13. Ziegler E J, Fischer C J Jr, Sprung C L, Straube R C, Sadoff J C, Foulke G E, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind placebo-controlled trial. N Engl J Med 1991; 324:429-36.
14. McCloskey R V, Straube R L, Sanders C, Smith S M, Smith C R. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized double-blind placebo-controlled trial. Ann Intern Med 1994; 121:1-5.
15. Greenman R L, Schein R M, Martin M A, Wenzol R P, MacIntyre N R, Emmanual G F, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 166:1097-102.
16. Bone R C, Balk R A, Fein A M, Perl T M, Wenzel R P, Reines H D, et al. A second large controlled clinical trial of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicentre, randomized, controlled trial. Crit Care Med 1995; 23:994-1005.
17. Wought S D, Ramos R A, Hermanowski-Vosatka A, Rodwell P, Detruers P A. Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14. J Exp Med 1991; 173:1281-6.
18. Kohn F R, Ammons W S, Horwitz A, Grinna L, Theofan G, Weickmann J, et al. Protective effect of a recombinant amino-terminal fragment of bactericidal permeability-increasing protein in experimental endotoxemia. J Infect Dis 1993; 168:1307-10.
19. Hirata M, Shimomura Y, Yoshida M, Morgan J G, Palings I, Wilson D, et al. Characterisation of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun 1994; 62:1421-6.
20. Ooi C E, Weiss J, Levy O, Elsbach P. Isolation of two isoforms of a novel 15-kDa protein from rabbit polymorphonuclear leukocytes that modulate the antibacterial actions of other leukocyte proteins. J Biol Chem 1990; 265:15956-62.
21. Morrison D C, Jacobs D M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccherides. Immunochemistry 1996; 13:813-8.
22. Vosika G J, Barr C, Gilbertson D. Phase-1 study of intravenous modified lipid A. Cancer Immunol Immunother 1984; 18:101-12.
23. Abraham E, Wunderink R, Silverman H, Perl T M, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumour necrosis factor in patients with sepsis syndrome. JAMA 1995; 273:934-41.
24. Cohen J, Carlet J. INTERSEPT: an international multicenter, placebo-controlled trial of monoclonal antibody (MAb) to human tumour necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-40.
25. Fischer C J Jr, Agnosti J M, Opal S M, Lowry S F, Balk R A, Sadoff J C, et al. Treatment of septic shock with the tumour necrosis factor receptor : Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-702.
26. Ohlsoon K, Bjork P, Bergenfeldt M, Hageman R, Thompson R C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-2.
27. Fischer C J, Slotman G J, Opal S M, Pribble J P, Bone R C, Emmanuel G, et al. Initial evaluation of recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized open label, placebo controlled multicenter trial. Crit Care Med 1994; 22:12-21.
28. Fischer C J, Dhainaut J F, Opal S M, Balk R A, Slotman G J, Iberti T J, et al. Recombinant human interleukin-1 receptor-antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271:1836-43.
29. Bone R C, Fischer C J Jr, Clemmer T P, Slotman G J, Metz C A, Balk R A. A controlled clinical trial of high-dose methyl prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-8.
30. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659-65.
31. Dhainaut J F, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet J P, Wolff M, et al. Platelet activation factor receptor antagonist BN52021 in the treatment of severe sepsis: a randomized double placebo controlled, multicentre clinical trial. Crit Care Med 1994; 22:1720-8.
32. Bernard G R, Wheeler A P, Russell J A, Schein R, Summer W R, Steinberg K P, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336:912-8.
33. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21:1635-42.
34. Daemen-Gubbek C R, Groeneveld P H, Groeneveld A B, van Kamp G J, Bonsweld W, Thijs L G. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995; 23:1363-70.
35. Cobb J P, Danner R L. Nitric oxide and septic shock. JAMA 1996; 275:1192-6.
36. G-monomethyl-L-arginine. J Cardiovasc Pharmacol 1992; 20(Suppl 12):S132-4.
37. Petros A, Bennett D, Vallence P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338:1557-8.
38. Friedman G, Jankowski S, Shahla M, Goldman M, Rose R M, Kahn R J, et al. Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med 1996; 24:229-33.
39. Stegmayr B G. Plasmapheresis in severe sepsis or septic shock. Blood Purification 1996; 14:94-101.
40. Gardlund B. Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis 1993; 25:757-61.